Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
about
S100A9 interaction with TLR4 promotes tumor growthA Perspective of Immunotherapy for Prostate CancerNew drugs in prostate cancerTasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospectsGrowth factor and signaling pathways and their relevance to prostate cancer therapeuticsAnti-angiogenesis in prostate cancer: knocked down but not outSystemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancerRecent progress in pharmaceutical therapies for castration-resistant prostate cancerMechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancerNovel non-AR therapeutic targets in castrate resistant prostate cancerBone-targeting agents in prostate cancer.Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050).Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer.Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancerTasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine modelsS100 proteins in cancer.Emerging targeted therapies for castration-resistant prostate cancer.The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b(+) Ly6C(hi) cells to tumor tissue reduces tumor growthInflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseasesCurrent and emerging therapies for bone metastatic castration-resistant prostate cancer.Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment.Elevated S100A9 expression in tumor stroma functions as an early recurrence marker for early-stage oral cancer patients through increased tumor cell invasion, angiogenesis, macrophage recruitment and interleukin-6 production.The changing landscape in the treatment of metastatic castration-resistant prostate cancer.S100A12 and the S100/Calgranulins: Emerging Biomarkers for Atherosclerosis and Possibly Therapeutic Targets.Novel therapies for the treatment of advanced prostate cancer.Review of S100A9 biology and its role in cancer.Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancerImmunotherapy and immune evasion in prostate cancer.Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancerControversies on individualized prostate cancer care: gaps in current practice.S100A8 and S100A9: DAMPs at the crossroads between innate immunity, traditional risk factors, and cardiovascular disease.S100 protein family in human cancer.Targeting angiogenesis for the treatment of prostate cancer.Management of metastatic castration-resistant prostate cancer: recent advances.Chemotherapy for prostate cancer: when should a urologist refer a patient to a medical oncologist?Current and emerging treatments in the management of castration-resistant prostate cancer.Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancer.Roles of microRNAs during prostatic tumorigenesis and tumor progression.A review of tasquinimod in the treatment of advanced prostate cancer.
P2860
Q21134707-9D81B700-A19F-4FD0-ACCF-7A6E06CC8853Q26741277-5A40F39D-BEF1-47D9-B7C6-700A1A2DB766Q26745948-76A9105B-78DD-4AE3-BF2A-18741DA9F2F3Q26770428-A97C3FE7-1380-4FAA-96C4-DCD519CF309BQ26827975-2B93CFB0-724E-4A87-8A79-A99062C710B0Q26851183-43C675CA-1D60-42B9-BE76-13D26A6793C7Q26852544-EEA61790-53E5-4E73-83D2-578929F8C8EBQ27010542-44A1136C-D4BF-4DA1-B43C-CAC6DE58CBF0Q27022567-B814F809-AAF1-47F9-91E1-E669B9EC28F1Q27024795-344E8729-9441-4667-B8CD-9968777477F1Q28383663-97418588-6C77-46F0-A13D-1E0BF2382CB6Q33864723-BC42D87F-F6D0-41A9-804E-E74332F1236FQ34250496-AC33BA98-1FD0-408A-A7E1-6DD6006FEC61Q34323756-4C17AA44-5B5F-4109-9C5F-1997E8CCE5CBQ34608976-99AC56B5-C7BF-4AAE-9872-D13222D210EFQ35071167-A629331D-BA3E-4776-A2B0-580851A78335Q35206368-55908DBB-70CA-47FC-905F-EB5382234193Q35999255-145B92C6-7815-49F5-A19D-530824F3145DQ36072831-762F51F5-C532-499A-83E8-842E0044371FQ36299678-F74A8E35-6FBE-43E6-A602-8EABBB3F4B9BQ36358303-E7136F82-DA4E-44CF-BA5B-4F4CB412D0BCQ36370409-81BC458F-CD46-4727-8E5B-499D4BC4991EQ36414066-1970D081-4F14-4E71-942A-8DF6D191087EQ36515526-F3E51250-2063-4867-9E37-2CF454222B1FQ36631781-67A7E743-E2EE-4BD2-923D-E5350B72A43EQ36665708-0A699B37-D7C4-4340-BA32-878414548275Q36896567-E5B58C9E-64B3-4664-9BE1-DC344CAEC76AQ36931715-A0DF9D52-43C3-4FBC-A349-2CDAA6F97297Q37061769-15A8B130-E307-42E5-943D-5D946E78B573Q37113485-511F778D-29DE-4EF1-9E59-153A7FB789FEQ37149085-1403C2A7-4687-4D8A-8D13-92306990DA5BQ37436729-FC1BB8A3-82C3-443F-815D-649632CF48AAQ37650123-55D56461-4516-42A5-B487-3C5531665237Q37993137-C943FABB-8982-4FF0-A179-D9C5878400EBQ38012528-81BA400B-E452-43D7-A2B8-7012E679208CQ38023123-AEAF40DE-B7D1-4E68-99EF-0101174EB00BQ38030595-7ABBB442-2917-4E9D-BE5B-1E82FBB5D59FQ38075446-0C1890AC-92D6-4F23-B058-834064B4DED6Q38086009-8337E783-BA2A-4CA6-A356-D21C2C7AFBFEQ38105544-A0E05F3C-A861-4DB1-AEAF-4483B9F87129
P2860
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Phase II randomized, double-bl ...... ate-resistant prostate cancer.
@ast
Phase II randomized, double-bl ...... ate-resistant prostate cancer.
@en
Phase II randomized, double-bl ...... ate-resistant prostate cancer.
@nl
type
label
Phase II randomized, double-bl ...... ate-resistant prostate cancer.
@ast
Phase II randomized, double-bl ...... ate-resistant prostate cancer.
@en
Phase II randomized, double-bl ...... ate-resistant prostate cancer.
@nl
prefLabel
Phase II randomized, double-bl ...... ate-resistant prostate cancer.
@ast
Phase II randomized, double-bl ...... ate-resistant prostate cancer.
@en
Phase II randomized, double-bl ...... ate-resistant prostate cancer.
@nl
P2093
P356
P1476
Phase II randomized, double-bl ...... ate-resistant prostate cancer.
@en
P2093
Anders Björk
Andrew J Armstrong
Goran Forsberg
Jeffrey R Gingrich
Michael A Carducci
Michael Häggman
Orjan Nordle
Roberto Pili
Vasileios J Assikis
Walter M Stadler
P304
P356
10.1200/JCO.2011.35.6295
P407
P577
2011-09-19T00:00:00Z